@article{HircheKnoopHebestreitetal.2014,
  author    = {Hirche, T. O. and Knoop, C. and Hebestreit, H. and Shimmin, D. and Sol{\´e}, A. and Elborn, J. S. and Ellemunter, H. and Aurora, P. and Hogardt, M. and Wagner, T. O. F.},
  title     = {Practical Guidelines: Lung Transplantation in Patients with Cystic Fibrosis},
  series = {Pulmonary Medicine},
  volume    = {2014},
  journal   = {Pulmonary Medicine},
  organization    = {ECORN-CF Study Group},
  issn      = {2090-1836},
  doi       = {10.1155/2014/621342},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-121569},
  pages     = {621342},
  year      = {2014},
  abstract  = {There are no European recommendations on issues specifically related to lung transplantation (LTX) in cystic fibrosis (CF). The main goal of this paper is to provide CF care team members with clinically relevant CF-specific information on all aspects of LTX, highlighting areas of consensus and controversy throughout Europe. Bilateral lung transplantation has been shown to be an important therapeutic option for end-stage CF pulmonary disease. Transplant function and patient survival after transplantation are better than in most other indications for this procedure. Attention though has to be paid to pretransplant morbidity, time for referral, evaluation, indication, and contraindication in children and in adults. This review makes extensive use of specific evidence in the field of lung transplantation in CF patients and addresses all issues of practical importance. The requirements of pre-, peri-, and postoperative management are discussed in detail including bridging to transplant and postoperative complications, immune suppression, chronic allograft dysfunction, infection, and malignancies being the most important. Among the contributors to this guiding information are 19 members of the ECORN-CF project and other experts. The document is endorsed by the European Cystic Fibrosis Society and sponsored by the Christiane Herzog Foundation.},
  language  = {en}
}
@article{HebestreitLandsAlarieetal.2018,
  author    = {Hebestreit, Helge and Lands, Larry C. and Alarie, Nancy and Schaeff, Jonathan and Karila, Chantal and Orenstein, David M. and Urquhart, Don S. and Hulzebos, Erik H. J. and Stein, Lothar and Schindler, Christian and Kriemler, Susi and Radtke, Thomas},
  title     = {Effects of a partially supervised conditioning programme in cystic fibrosis: an international multi-centre randomised controlled trial (ACTIVATE-CF): study protocol},
  series = {BMC Pulmonary Medicine},
  volume    = {18},
  journal   = {BMC Pulmonary Medicine},
  doi       = {10.1186/s12890-018-0596-6},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-227960},
  year      = {2018},
  abstract  = {Background Physical activity (PA) and exercise have become an accepted and valued component of cystic fibrosis (CF) care. Regular PA and exercise can positively impact pulmonary function, improve physical fitness, and enhance health-related quality of life (HRQoL). However, motivating people to be more active is challenging. Supervised exercise programs are expensive and labour intensive, and adherence falls off significantly once supervision ends. Unsupervised or partially supervised programs are less costly and more flexible, but compliance can be more problematic. The primary objective of this study is to evaluate the effects of a partially supervised exercise intervention along with regular motivation on forced expiratory volume in 1 s (FEV1) at 6 months in a large international group of CF patients. Secondary endpoints include patient reported HRQoL, as well as levels of anxiety and depression, and control of blood sugar. Methods/design It is planned that a total of 292 patients with CF 12 years and older with a FEV1 ≥ 35\% predicted shall be randomised. Following baseline assessments (2 visits) patients are randomised into an intervention and a control group. Thereafter, they will be seen every 3 months for assessments in their centre for one year (4 follow-up visits). Along with individual counselling to increase vigorous PA by at least 3 h per week on each clinic visit, the intervention group documents daily PA and inactivity time and receives a step counter to record their progress within a web-based diary. They also receive monthly phone calls from the study staff during the first 6 months of the study. After 6 months, they continue with the step counter and web-based programme for a further 6 months. The control group receives standard care and keeps their PA level constant during the study period. Thereafter, they receive the intervention as well. Discussion This is the first large, international multi-centre study to investigate the effects of a PA intervention in CF with motivational feedback on several health outcomes using modern technology. Should this relatively simple programme prove successful, it will be made available on a wider scale internationally. Trial registration ClinicalTrials.gov Identifier: NCT01744561; Registration date: December 6, 2012.},
  language  = {en}
}